



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ingle, DJ;Andersson, P;Valcanis, M;Barnden, J;da Silva, AG;Horan, KA;Seemann, T;Easton, M;Williamson, DA;Sherry, NL;Howden, BP

Title:

Prolonged Outbreak of Multidrug-Resistant *Shigella sonnei* Harboring blaCTX-M-27 in Victoria, Australia

Date:

2020-12-01

Citation:

Ingle, D. J., Andersson, P., Valcanis, M., Barnden, J., da Silva, A. G., Horan, K. A., Seemann, T., Easton, M., Williamson, D. A., Sherry, N. L. & Howden, B. P. (2020). Prolonged Outbreak of Multidrug-Resistant *Shigella sonnei* Harboring blaCTX-M-27 in Victoria, Australia. *Antimicrobial Agents and Chemotherapy*, 64 (12), <https://doi.org/10.1128/AAC.01518-20>.

Persistent Link:

<https://hdl.handle.net/11343/252211>

License:

CC BY

1 **Title: Prolonged outbreak of multidrug-resistant *Shigella sonnei* harbouring *bla*CTX-**  
2 **M-27 in Victoria, Australia**

3

4 **Authors:**

5 Danielle J. Ingle<sup>1,2\*</sup>, Patiyán Andersson<sup>1\*</sup>, Mary Valcanis<sup>1</sup>, Jessica Barnden<sup>1</sup>, Anders

6 Gonçalves da Silva<sup>1</sup>, Kristy A. Horan<sup>1</sup>, Torsten Seemann<sup>1</sup>, Marion Easton<sup>3</sup>, Deborah A.

7 Williamson<sup>1,4</sup>, Norelle L. Sherry<sup>1,4</sup>, and Benjamin P. Howden<sup>1,5</sup>

8

9 **Affiliations:**

10 <sup>1</sup> *Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and*  
11 *Immunology at the Peter Doherty Institute for Infection and Immunity, The University of*  
12 *Melbourne, Melbourne, Australia*

13 <sup>2</sup> *Research School of Population Health, Australian National University, Canberra, Australia*

14 <sup>3</sup> *Department of Health and Human Services, Victoria, Australia*

15 <sup>4</sup> *Department of Microbiology, Melbourne Health, Victoria, Australia*

16 <sup>5</sup> *Doherty Applied Microbial Genomics, Department of Microbiology and Immunology at the*  
17 *Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne,*  
18 *Australia*

19

20 \* These authors contributed equally. Order of names was decided by DJI also acting as one  
21 of the two corresponding authors.

22 Corresponding authors:

23 DJI [danielle.ingle@unimelb.edu.au](mailto:danielle.ingle@unimelb.edu.au) and BPH [bhowden@unimelb.edu.au](mailto:bhowden@unimelb.edu.au)

24

25

26 **Abstract**

27 **Objectives**

28 In Australia, cases of shigellosis usually occur in returned travellers from shigellosis-endemic  
29 regions, or in men who have sex with men. Resistance to multiple antibiotics has  
30 significantly increased in *Shigella sonnei* and represents a significant public health concern.  
31 Here we investigate an outbreak of multidrug-resistant *S. sonnei* in Victoria, Australia.

32 **Methods**

33 We undertook whole genome sequencing of 54 extended-spectrum beta-lactamase (ESBL)  
34 producing *S. sonnei* received at the Microbiological Diagnostic Unit Public Health Laboratory  
35 between January 2019 and March 2020. The population structure and antimicrobial  
36 resistance profiles were identified by genomic analyses, with 73 previously characterised  
37 Australian *S. sonnei* to provide context. Epidemiological data including age and sex of the  
38 shigellosis cases were also collected.

39 **Results**

40 There was a significant increase in cases of ESBL *S. sonnei* from July 2019. Most of the  
41 ESBL *S. sonnei* (65%) fell within a single cluster, that was predominantly comprised of male  
42 cases, and were characterised by the presence of *bla*CTX-M-27 gene conferring resistance  
43 to extended-spectrum cephalosporins. These isolates were also multidrug-resistant,  
44 including resistance to azithromycin and co-trimoxazole and reduced susceptibility to  
45 ciprofloxacin.

46 **Conclusions**

47 Our data has uncovered a prolonged clonal outbreak of ESBL *S. sonnei* that was likely first  
48 introduced by returned travellers and has subsequently been circulating locally in Australia.  
49 The emergence of a local outbreak of ESBL *S. sonnei*, with a multidrug-resistant profile,  
50 including reduced susceptibility to ciprofloxacin, represents a significant public health threat.

51

## 52 Introduction

53 *Shigella* species are one of the leading causative agents for severe diarrhoeal disease  
54 globally(1, 2). While the burden of disease is disproportionately experienced by children  
55 under the age of five in low- and middle-income countries (LMICs)(1), in high-income  
56 countries (HICs) cases of shigellosis are usually associated with either returned travellers or  
57 in men who have sex with men (MSM)(3-5). Endemic shigellosis in men in HICs is often  
58 considered a sexually transmitted infection (STI), with several *Shigella sonnei* and *Shigella*  
59 *flexneri* lineages associated with MSM outbreaks(6-8).

60

61 A common characteristic of the MSM-associated outbreaks of *Shigella* infections is the  
62 prevalence of multidrug resistance (MDR) to critical oral therapeutics; ciprofloxacin is the  
63 first-line agent, with azithromycin or co-trimoxazole being second-line agents. Antimicrobial  
64 resistance (AMR) to azithromycin and co-trimoxazole is usually mediated by the acquisition  
65 of an MDR plasmid(7), while resistance to ciprofloxacin, reported in MSM-associated *S.*  
66 *sonnei*, is due to point mutations in quinolone resistance determining regions (QRDRs)(5). In  
67 the presence of resistance to oral agents, the most frequently used treatment option for  
68 severe shigellosis is third-generation (extended-spectrum) cephalosporins such as  
69 ceftriaxone or cefotaxime, which are given intravenously(9). Sporadic cases of extended-  
70 spectrum beta-lactamase (ESBL) producing *S. sonnei* have been previously reported, often  
71 in association with travel to Asia(6, 10, 11), but these have not been associated with  
72 prolonged outbreaks.

73

74 Here, we investigated the recent increase of ESBL-resistant *S. sonnei* reported from late  
75 2019 to early 2020 in the state of Victoria, Australia. We used whole-genome sequence  
76 (WGS) data of *S. sonnei*, combining it with epidemiological data, and contextualising these  
77 ESBL isolates with previously characterised Australian *S. sonnei* isolates, to demonstrate  
78 the emergence of an ESBL-resistant lineage of *S. sonnei* circulating in males since October  
79 2019.

80

81 **Methods**

82 Shigellosis is a notifiable disease in Australia. The Microbiological Diagnostic Unit Public  
83 Health Laboratory (MDU PHL) is the bacteriology reference laboratory for the State of  
84 Victoria (population approximately 6.4 million). MDU PHL receives *Shigella* isolates from  
85 primary pathology laboratories for the purpose of further characterisation, including  
86 phenotypic susceptibility testing and routine WGS. All *S. sonnei* received by the MDU PHL  
87 from 1 January 2019 to 31 March 2020 were assessed for the ESBL markers (resistance to  
88 ceftriaxone and presence of ESBL gene on WGS). The 54 ESBL-producing isolates  
89 identified also had associated epidemiological data including time of collection, sex and age  
90 of the patient. To compare ESBL *S. sonnei* notifications to a previous baseline period, seven  
91 sporadic ESBL *S. sonnei* received from 1 January 2019 to 30 May 2019 (previously  
92 published) were included(5). Details of the ESBL isolates are in **Supplementary Table 1**,  
93 and short read data are available at BioProject PRJNA319594.

94

95 DNA extracts from 47 novel ESBL isolates were prepared using Illumina Nextera XT DNA  
96 library chemistry and whole-genome sequenced on a NextSeq500 or NextSeq550.  
97 Sequences from 73 Australian *S. sonnei* broadly representative of the diversity of the  
98 previously-established population structure were included to provide a contextual framework  
99 for the ESBLs *S. sonnei*(4, 5). The 127 genomes were mapped to the reference *S. sonnei*  
100 (accession CP000038) to call single nucleotide polymorphisms (SNPs) using Snippy v.4.6.0,  
101 with filtering of phage regions identified using PHASTER(12), resulting in a core SNP  
102 alignment of 4,849 bases. A maximum likelihood (ML) phylogeny was inferred using IQTree  
103 (v.1.6.12)(13) and a GTR+G4 model. The resulting ML phylogeny was mid-point rooted with  
104 ape (v.5.3)(14) and phangorn (v.2.5.5)(15), before being visualised with ggtree  
105 (v.1.16.6)(16).

106

107 *De novo* assembly was performed using SPAdes (v.3.14.0)(17) using the ‘-isolate’ flag. *In*  
108 *silico* determination of known AMR genes in the AMRfinderPlus database using abriTAMR  
109 (v.2020-01-22.1) (<https://github.com/MDU-PHL/abritamr>). Known point mutations in the  
110 QRDRs of *gyrA* and *parC* were identified from Snippy output. Pairwise SNP distances  
111 between isolates were determined using harrietR (v.0.2.3)  
112 (<https://github.com/andersgs/harrietr>) in R (v.3.6.1).

113

## 114 **Results and Discussion**

115 In total, 54 *S. sonnei* ESBL isolates were identified in Victoria in the 15 months between  
116 January 2019 and March 2020. The inferred population structure in **Figure 1A** shows the  
117 ESBL isolates were distributed within previously defined lineages(4). In the baseline period  
118 (January 2019 to May 2019), six isolates fell in Lineage 1 and one in Lineage 4. Of the 47  
119 novel ESBL isolates received in the study period (June 2019 and March 2020), 35/47  
120 (74.5%) fell in Lineage 3, while Lineage 1 and Lineage 4 each comprised six novel ESBL  
121 isolates (**Figure 1A**). The 35 ESBL Lineage 3 isolates formed a genomic cluster, highly  
122 suggestive of an outbreak, with a median pairwise distance of 3 SNPs (interquartile range 2-  
123 4 SNPs). These 35 putative outbreak isolates and two contextual isolates were  
124 characterised by the presence of the ESBL resistance gene *bla*CTX-M-27, accompanied by  
125 additional AMR determinants including *mphA* (azithromycin resistance), *dfrA1* and *sul2*  
126 (co-trimoxazole resistance), and decreased susceptibility to ciprofloxacin with a single point  
127 mutation in *gyrA* (S83L). Together these genes confer resistance to the critical oral  
128 antibiotics plus extended-spectrum cephalosporins, such as ceftriaxone.

129

130 There was a marked increase in ESBL *S. sonnei* in late 2019 and early 2020 compared to  
131 early 2019 with 43/54 (76%) of cases occurring from October 2019 onwards, (**Figure 1B**).  
132 The increase was predominately due to isolates carrying *bla*CTX-M-27, with both the  
133 number and proportion of such isolates increasing over the quarters (Q1-2019, 0/1 (0%);  
134 Q2-2019, 1/6 (17%); Q3-2019, 1/5 (20%); Q4-2019 13/19 (70%); Q1-2020, 23/23 (100%). All

135 but 3/38 *bla*CTX-M-27 were part of Lineage 3. The remaining three isolates with *bla*CTX-M-  
136 27 fell in Lineage 1 and were also characterised by three-point mutations in QRDRs.  
137 However, the diversity of the AMR profile and demographic characteristics combined with  
138 the relatively low incidence of ESBL cases in Lineage 1, suggest these ESBL isolates are  
139 likely to be sporadic introductions from different sources. Indeed, the ESBL isolates in  
140 Lineage 1 and Lineage 4 had greater diversity of *bla*CTX-M genes compared to Lineage 3,  
141 with the *bla*CTX-M-14 or *bla*CTX-M-15 the more common ESBL mechanisms (**Figure 1A-**  
142 **B**).

143

144 The population demographics of the cluster of *bla*CTX-M-27 genomes in Lineage 3 is  
145 notably different from the sporadic ESBL cases in other lineages and highly indicative of a  
146 prolonged outbreak event in Australia. Lineage 3 has been previously associated with a high  
147 proportion of cases where the identified primary risk factor was MSM(4), and in this study,  
148 33/35 (94%) of cases were men (**Figure 1C**). The first case in the cluster occurred in  
149 September 2019, followed by 2-12 cases per month through to the end of the study period.  
150 The epidemic curve is highly suggestive of an outbreak event. Further, we note the AMR  
151 profile of these Australian ESBL isolates is consistent with that of a cluster of MDR *S.*  
152 *sonnei*, with the same ESBL gene *bla*CTX-M-27, that was detected in the United Kingdom  
153 between March and November 2018, and identified in a public health alert by Public Health  
154 England (PHE)(18). The PHE alert notes some of the ESBL *S. sonnei* isolates also clustered  
155 with isolates from cases in the USA from male patients who identified as MSM(18). While  
156 investigation of the global prevalence of ESBL *S. sonnei* was beyond the scope of this study,  
157 it does suggest the potential global dissemination of this ESBL sub-lineage and highlights  
158 the need for future public health surveillance to be able rapidly identify and classify high risk  
159 outbreak lineages. Notably, two contextual isolates, which had been previously  
160 characterised from returned travellers to south-east Asia(4), had the same AMR profile as  
161 the ESBL outbreak cluster. These two isolates were taken from female patients in 2017,  
162 which indicates this sub-lineage was circulating in south-east Asia at this time. This is

163 suggestive that this sub-lineage of ESBL *S. sonnei* may have been introduced to Australia  
164 by a returned traveller from this region, and then gone on to be locally transmitted.

165

166 Here we report the emergence of a prolonged outbreak of ESBL resistant *S. sonnei* in  
167 Victoria. This represents a significant public health threat with members of this prolonged  
168 outbreak now resistant to ceftriaxone, co-trimoxazole and azithromycin and reduced  
169 susceptibility to ciprofloxacin. The latent spread of this ESBL lineage in Victoria has likely  
170 occurred in populations with high antimicrobial exposure, coupled with high resistance  
171 potential with an existing QRDR mutation, and poses a significant concern for this lineage to  
172 become resistant to ciprofloxacin. This could have serious clinical implications, necessitating  
173 the use of extremely broad-spectrum antimicrobials such as carbapenems, and reducing the  
174 likelihood of a patient receiving the correct empiric therapy prior to the identification of the  
175 MDR *Shigella*. Our data also demonstrates the power of enhanced surveillance of enteric  
176 pathogens through genomic epidemiology and highlights the need for systematic reporting  
177 on ESBL resistance in *Shigella* species, which is not currently required in Australian public  
178 health laboratories.

179

180 **Figure Legend**

181

182 **Figure 1: Population structure and antimicrobial resistance profiles of ESBL *Shigella***  
183 ***sonnei***

184 A. The mid-point rooted phylogenetic tree of 54 ESBL *Shigella sonnei* and 73 contextual  
185 isolates. The tips are coloured by ESBL status for the novel isolates and by membership to  
186 previously established lineages for the contextual isolates. The sex of the patient is shown to  
187 the right of the phylogeny. Known genetic determinants for critical antimicrobials are shown  
188 as a heatmap. The \* next to the gene indicates a partial match (partial gene recovery occurs  
189 when between 50% and 90% of a protein in the AMRfinder database is covered by a contig  
190 at >90% identity). B. Epidemic curve of ESBL *S. sonnei*, coloured by ESBL gene, received at  
191 MDU PHL between 1 January 2019 and 30 March 2020. C. The patient characteristics of  
192 the 35 *S. sonnei* isolates in ESBL outbreak lineage with the histogram stratified by age  
193 group and sex.

194 **Funding**

195 This work was supported by National Health and Medical Research Council (NHMRC)  
196 Australia Partnership Grant (APP1149991). BPH was supported by NHMRC Practitioner  
197 Fellowship (APP1105905). The Microbiological Diagnostic Unit Public Health Laboratory is  
198 funded by the Victorian Government.

199

200 **Transparency declarations**

201 None to declare.

202

203 **References**

- 204 1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S,  
205 Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL,  
206 Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo  
207 S, Ochieng JB, Omere R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S,  
208 Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I,  
209 Nhampossa T, Acácio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY,  
210 Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and  
211 aetiology of diarrhoeal disease in infants and young children in developing  
212 countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-  
213 control study. *The Lancet* 382:209–222.
- 214 2. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SR, Albertson SB,  
215 Stanaway JD, Deshpande A, Abebe Z, Alvis-Guzman N, Amare AT, Asgedom  
216 SW, Anteneh ZA, Antonio CAT, Aremu O, Asfaw ET, Atey TM, Atique S,  
217 Avokpaho EFGA, Awasthi A, Ayele HT, Barac A, Barreto ML, Bassat Q, Belay  
218 SA, Bensenor IM, Bhutta ZA, Bijani A, Bizuneh H, eda-Orjuela CAC, Dadi AF,  
219 Dandona L, Dandona R, Do HP, Dubey M, Dubljanin E, Edessa D, Endries AY,  
220 Eshрати B, Farag T, Feyissa GT, Foreman KJ, Forouzanfar MH, Fullman N,  
221 Gething PW, Gishu MD, Godwin WW, Guagnani HC, Gupta R, Hailu GB, Hassen  
222 HY, Hibstu DT, Ilesanmi OS, Jonas JB, Kahsay A, Kang G, Kasaeian A, Khader  
223 YS, Khalil IA, Khan EA, Khan MA, Khang Y-H, Kissoon N, Kochhar S, Kotloff  
224 KL, Koyanagi A, Kumar GA, Razek EI HMA, Malekzadeh R, Malta DC, Mehata  
225 S, Mendoza W, Mengistu DT, Menota BG, Mezgebe HB, Mlashu FW, Murthy S,  
226 Naik GA, Nguyen CT, Nguyen TH, Ningrum DNA, Ogbo FA, Olagunju AT,  
227 Paudel D, Platts-Mills JA, Qorbani M, Rafay A, Rai RK, Rana SM, Ranabhat CL,  
228 Rasella D, Ray SE, Reis C, Renzaho AM, Rezai MS, Ruhago GM, Safiri S,  
229 Salomon JA, Sanabria JR, Sartorius B, Sawhney M, Sepanlou SG, Shigematsu  
230 M, Sisay M, Somayaji R, Sreeramareddy CT, Sykes BL, Taffere GR, Topor-  
231 Madry R, Tran BX, Tuem KB, Ukwaja KN, Vollset SE, Walson JL, Weaver MR,  
232 Weldegwergs KG, Werdecker A, Workicho A, Yenesew M, Yirsaw BD,  
233 Yonemoto N, Sayed Zaki El M, Vos T, Lim SS, Naghavi M, Murray CJ, Mokdad  
234 AH, Hay SI, Reiner RC Jr, Collaborators G2DD. 2018. Estimates of the global,  
235 regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195  
236 countries: a systematic analysis for the Global Burden of Disease Study 2016.  
237 *Lancet Infect Dis* 18:1211–1228.
- 238 3. Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill F-X, Lefevre  
239 S, Tourdjman M, Hughes G, Jenkins C, Thomson N. 2018. Genomic  
240 epidemiology of *Shigella* in the United Kingdom shows transmission of pathogen  
241 sublineages and determinants of antimicrobial resistance. *Sci Rep* 8: 7389
- 242 4. Ingle DJ, Easton M, Valcanis M, Seemann T, Kwong JC, Stephens N, Carter  
243 GP, Gonçalves da Silva A, Adamopoulos J, Baines SL, Holt KE, Chow EPF,  
244 Fairley CK, Chen MY, Kirk MD, Howden BP, Williamson DA. 2019. Co-  
245 circulation of Multidrug-resistant *Shigella* Among Men Who Have Sex With Men  
246 in Australia. *Clin Infect Dis* 69: 1535-1544.
- 247 5. Williamson DA, Ingle DJ, Howden BP. 2019. Extensively Drug-Resistant  
248 Shigellosis in Australia among Men Who Have Sex with Men. *N Engl J Med*  
249 381: 2477–2479.
- 250 6. Mook P, McCormick J, Bains M, Cowley LA, Chattaway MA, Jenkins C, Mikhail  
251 A, Hughes G, Elson R, Day M, Manuel R, Dave J, Field N, Godbole G, Dallman  
252 T, Crook P. 2016. ESBL-Producing and Macrolide-Resistant *Shigella sonnei*

- 253 Infections among Men Who Have Sex with Men, England, 2015. *Emerg Infect*  
254 *Dis* 22:1948–1952.
- 255 7. Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, Weill F-X, Lefèvre  
256 S, Tourdjman M, Hughes G, Jenkins C, Thomson N. 2018. Horizontal  
257 antimicrobial resistance transfer drives epidemics of multiple *Shigella* species.  
258 *Nat Commun* 9: 1462.
- 259 8. Bardsley M, Jenkins C, Mitchell HD, Mikhail AFW, Baker KS, Foster K, Hughes  
260 G, Dallman TJ. 2020. Persistent Transmission of Shigellosis in England Is  
261 Associated with a Recently Emerged Multidrug-Resistant Strain of *Shigella*  
262 *sonnei*. *J Clin Microbiol* 58:909–11.
- 263 9. Antibiotic Expert Group. 2019. Acute infectious diarrhoea. *In* eTG complete  
264 digital. Melbourne. Available at: <https://www.tg.org.au>.
- 265 10. Hrabak J, Empel J, Gniadkowski M, Halbhuber Z, Rebl K, Urbaskova P. 2008.  
266 CTX-M-15-Producing *Shigella sonnei* Strain from a Czech Patient Who Traveled  
267 in Asia. *J Clin Microbiol* 46:2147–2148.
- 268 11. Lee W, Chung H-S, Lee H, Yum JH, Yong D, Jeong SH, Lee K, Chong Y. 2013.  
269 CTX-M-55-Type Extended-Spectrum  $\beta$ -lactamase-Producing *Shigella sonnei*  
270 Isolated from a Korean Patient Who Had Travelled to China. *Ann Lab Med*  
271 33:141–4.
- 272 12. Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, Wishart DS. 2016.  
273 PHASTER: a better, faster version of the PHAST phage search tool. *Nucleic*  
274 *Acids Res* 44:W16–W21.
- 275 13. Nguyen LT, Schmidt HA, Haeseler von A, Minh BQ. 2015. IQ-TREE: A Fast and  
276 Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies.  
277 *Mol Biol Evol* 32:268–274.
- 278 14. Paradis E, Claude J, Strimmer K. 2004. APE: analyses of phylogenetics and  
279 evolution in R language. *Bioinformatics* 20:289–290.
- 280 15. Schliep KP. 2010. phangorn: phylogenetic analysis in R. *Bioinformatics* 27:592–  
281 593.
- 282 16. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2016. ggtree: an rpackage for  
283 visualization and annotation of phylogenetic trees with their covariates and other  
284 associated data. *Methods Ecol Evol*, 8:28–36.
- 285 17. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin  
286 VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N,  
287 Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A new genome assembly  
288 algorithm and its applications to single-cell Sequencing. *J Comput Biol* 19:455–  
289 477.
- 290 18. Public Health England. 2019. MDR *Shigella sonnei* cluster (CTX-M-27) probably  
291 associated with MSM. PHE Publications.
- 292

